Samsung Bioepis Co., Ltd.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$335Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
95clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $56K
2020 $56K
2021 $16K
2022 $15K
2023 $42K
2024 $85K
2025 $65K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Ophthalmology $64K
Medical Oncology $53K
Rheumatology $53K
Dermatology $47K
Hematology & Oncology $30K
Gastroenterology (Internal Medicine) $19K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Steven Feldman Winston Salem, NC Dermatology $45,508.49
Jonathan Kay Worcester, MA Rheumatology $36,863.52
Srinivas Sadda Pasadena, CA Ophthalmology $29,585.55
Gary Lyman Seattle, WA Medical Oncology $20,677.10
David Warrow Hagerstown, MD Ophthalmology $13,421.42
Terence Friedlander San Francisco, CA Hematology & Oncology $9,425.35
Mark Pegram Stanford, CA Medical Oncology $8,778.95
Peter Kaiser Cleveland, OH Ophthalmology $7,600.00
Vandana Abramson Nashville, TN Medical Oncology $7,345.35
Laurence Greenbaum Atlanta, GA Pediatric Nephrology $7,328.00

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.